EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes

Mohamed I Elsaid iD, Na Li iD, Stephen A Firkins iD, Vinod K Rustgi iD, Electra D Paskett iD, Chathur Acharya, K Rajender Reddy iD, Chien Wei Chiang, Khalid Mumtaz iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Mohamed I Elsaid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims We examined the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using real‐world data from the MarketScan database.

Methods

We conducted a retrospective cohort study of patients with MASLD cirrhosis and type 2 diabetes between 2012 and 2020. Cox proportional hazard models examine the association between GLP‐1RAs initiation, modelled as time‐dependent, and the risk of ALO, a composite endpoint defined by the first occurrence of hepatic decompensation(s), portal hypertension, hepatocellular carcinoma (HCC) or liver transplantation (LT). We used Overlap Propensity Score Weighting (OPSW) to account for confounding. The study included 459 GLP‐1RAs and 4837 non‐GLP‐1RAs patients.

Results

The non‐GLP‐1RAs patients presented with 1411 (29%) ALO over 7431.7 person years, while GLP‐1RAs patients had 32 (7%) ALO over 586.6 person years – risk rate difference 13.5 (95% CI: 11.4–15.7) per 100 person‐years. The OPSW‐adjusted risk of ALO was reduced by 36% (hazard ratio [HR]: 0.64; 95% CI: 0.54–0.76) in patients with vs. without GLP‐1RAs initiation. GLP‐1RAs initiation was associated with significant reductions in the adjusted risk of hepatic decompensation (HR: 0.74; 95% CI: 0.61–0.88), portal hypertension (HR: 0.73; 95% CI: 0.60–0.88), HCC (HR: 0.37; 95% CI: 0.20–0.63) and LT (HR: 0.24; 95% CI: 0.12–0.43).

Conclusion

The use of GLP‐1RAs was associated with significant risk reductions in long‐term adverse liver outcomes, including hepatic decompensation, portal hypertension, HCC and LT, in MASLD cirrhosis patients with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Carcinoma, HepatocellularLiver NeoplasmsFatty LiverMetabolic DiseasesHypertension, PortalHumansHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsRetrospective StudiesLiver Cirrhosis

Stichwörter der Autor:innen

adverse liver outcomesglucagon‐like Peptide‐1 receptor agonistshepatic decompensationoverlap propensity score weighting

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Internal Medicine, Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

ORCID-Profile: Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, K Rajender Reddy, Khalid Mumtaz

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Cancer Institute

Zitieren

APA

Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024). Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17925

Vancouver

Elsaid MI, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C, et al. Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17925

BibTeX
@article{Elsaid2024,
  author = {Elsaid, Mohamed I and Li, Na and Firkins, Stephen A and Rustgi, Vinod K and Paskett, Electra D and Acharya, Chathur and Reddy, K Rajender and Chiang, Chien Wei and Mumtaz, Khalid},
  title = {Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17925}
}
Kostenlos starten →